Specifically, there is a balance between small molecules and monoclonal antibody drugs (mAbs) in the realm of oncology super blockbuster drugs, while immunology appears dominated by monoclonal antibodies and protein-based treatments.
GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the three months ended June 30, 2019.